The Dose

Welcome to The Dose, which tackles the finances behind local health care and life sciences and points to the most interesting national analysis. Your host is J.K. Wall.

Most drug money in Indiana funds research. Is that good?

With federal research funding declining, drug companies are taking a larger role funding the medical research happening at IU and universities around the country. That's not the same thing as paying to market drugs, but it's hardly without controversy.
Read More

Doctors' drug money

Indiana physicians and research organizations reaped more than $25 million in payments from 15 pharmaceutical firms in 2012, according to the most recent data made available by the not-for-profit group ProPublica. Lilly was the biggest spender and the IU medical school was the biggest recipient.
Read More

A silver lining for Endocyte

The news this morning couldn’t have been worse for Endocyte Inc. But if it had to come, the timing couldn’t have been better--because it allowed Endocyte to raise a pile of cash to spend on the other drugs in its pipeline.
Read More

BioCrossroads drops dreams for hospital innovation

In this age of austerity, there's almost no chance of Indianapolis hospitals creating a Cleveland Clinic-like hub of innovation.
Read More